SEC Form 4 · accession 0001179110-18-001407
Celldex Therapeutics, Inc. · CLDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerald McMahon Ph.D.
Director
Period of report
Feb 1, 2018
Accepted (ET)
Feb 2, 2018 · 7:35 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000744218
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001 per shareF1,F2 | Feb 1, 2018 | F | 3,415 | $2.76 | D | 210,156 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On November 28, 2016, in connection with the Reporting Person's employment separation agreement with Kolltan Pharmaceuticals, Inc., Reporting Person entered into a severance agreement (the "Severance Agreement") with Celldex Therapeutics, Inc. ("Issuer") whereby Issuer agreed to pay Reporting Person 267,356 shares of its common stock, par value $0.001 per share ("Common Stock") less required tax and other withholdings (the "Withholdings".) The Reporting Person previously reported ownership of such 267,356 shares on his Form 3 filed with the Securities and Exchange Commission on December 15, 2016. The shares, less Withholdings, are issuable to Reporting Person in equal monthly installments through December 2018.
- F2Pursuant to the Severance Agreement, on February 1, 2018, the Issuer issued 4,939 shares of its Common Stock to the Reporting Person. This Form 4 reflects the disposition to the Issuer of 3,415 shares of its Common Stock to satisfy required Withholdings in connection with such issuance of Common Stock to the Reporting Person.